# Pharma / Biotech / Life Sciences Podcast Recap - Week of June 21, 2026: Biotech Is Back, and the Engine Is M&A From Patent Cliffs

> Pharma, biotech and life-sciences podcast recap for the week of June 14–21, 2026. UBS's Michael Yee declared 'biotech is back' on the back of a record M&A wave driven by the biggest patent cliffs the industry has ever faced, while ADA and ASCO supplied a flood of GLP-1 and oncology readouts.

## Pharma / Biotech / Life Sciences Podcast Recap

### Week of June 21, 2026: Biotech Is Back, and the Engine Is M&A From Patent Cliffs

---

**Coverage note:** A strong week for source material, ~50 relevant episodes after filtering. Two events dominated the calendar: ASCO 2026 / the National General Medical Oncology Summit (a large volume of clinical readout content) and the ADA 2026 Scientific Sessions (GLP-1 / obesity). The most actionable investor-grade commentary came from CNBC Fast Money (UBS biotech), Citeline Scrip, BioCentury, BioSpace, Value Hive, and a cluster of AI-in-discovery shows. Coverage was thin-to-absent on tools/CROs/medtech and on IRA negotiation mechanics, flagged in Section 6.

## Dominant Themes

**Biotech is "back," and the engine is M&A driven by patent cliffs.** The single loudest investment message of the week came from Michael Yee, UBS global head of biotech research, on CNBC's Fast Money. He framed the recovery as multi-year: "The resurgence is multi-year. I could see this playing out over the next year or two. Drug pricing is mostly behind us. And most importantly, the surge is being driven by a lot of M&A. There's record M&A numbers. Pharma's face the biggest patent cliffs that they've had ever. And these big pharma companies are buying up all the biotechs." ([CNBC's "Fast Money"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhIPVwR8Xv9q9VvJzigGgivq1lsuu5hKeSuKWNhCmsNDegQlyTH4TtHpai-2F3PhjXtzdk-2BGBg21E2Sej1ZWmbi1B0Q8-2FmXdBb9WeAxMhjxvnXQ-3D-3DwwKL_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoYefgBzGlZz1Id5pE7Tu2fdGdbCw9-2BexyQzBfBX3sGF9xLRRFH-2FI4lJFJgi52agQ4X-2BG4Gpl1zKHp5vTXlWJIX-2BcmcdIoX89oP7DLS7G1LulNVmjrf4gHoBh25R1b5xQaQ-3D-3D))

**The biotech IPO window has reopened, for de-risked, mid/late-stage assets.** Fast Money's Angelica Peebles noted the contrast with the pandemic boom ("172 biotechs went public in 2020 and 2021, raising around $36 billion," many preclinical, "selling investors on ideas rather than data"), whereas today's tape favors mature pipelines; NASDAQ's health-care listings lead told her it's "possible we'll see 25 biotech IPOs this year." ([CNBC's "Fast Money"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhIPVwR8Xv9q9VvJzigGgivq1lsuu5hKeSuKWNhCmsNDegQlyTH4TtHpai-2F3PhjXtzdk-2BGBg21E2Sej1ZWmbi1B0Q8-2FmXdBb9WeAxMhjxvnXQ-3D-3D5Eqa_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoeCmLVJvOoF3FEbsOGI2wWTwzdUUIkdG-2B7cBVTxjCyHVO-2BrWPWwkQN34uCD6qZKt7-2Fd2Mk4guLfs-2FolpMLkZAkQFCJJnVIGWoX56jkiTlakeD33OF-2BDHhHFHvheX-2Fd60aA-3D-3D)) BioCentury and BioSpace corroborated record raises: Parabolus priced "just north of 770 in millions" (over-allotment exercised), a new bar, and held up even as it printed the same week as the SpaceX mega-IPO; cardiac company Cardigan targeted ~$350M. ([BioCentury This Week](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgVMFhquD44R1J5rj8fptp-2Fb6UDC4PpVrtCoGaw0Sc6uYa68qj6dDkJqyLIlSXzRczKjNCBxPtmDqH8pxpzIKCS7Mx3zeo4U2ipuzbW0s7WOg-3D-3DLzry_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VobmIQIG1noJ6drDltoQ144W7A5aKHmgM0p9d6osiiaX5V6TDayT3QjDa3uZzbIspfgxUvwGpn6FXWW0uryblaQPUj72TI9TNu4t19y3yPRZjDklldZU-2F0JgYFXOxlqknnw-3D-3D)) Cell & Gene's editors added that "April was the most active IPO month in five years. Four companies raised over $1.5 billion," and leading biotech indices were up "a little over double digits for the first five months of the year." ([Cell & Gene: The Podcast](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjaBjZvdxWeFIWfM7d3z-2BpmvxRj5Z9mHSQU-2Brtabhb-2BcKyNbSA6JVB6p9EyIEwb-2FmaX1M8NnayBz6DRPpc-2BomDo3Yu2DfnCGZCIzCGQxiQrBg-3D-3DTTym_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoWWu4hxchXyIgMxVeCi1FbeFdzGhY3VKYfYvsWBipEtXG-2FumtPIYEzgrFlCbzFaim7Nf5aZElEMuQ2IQRdgBhxDlHuALTAME-2FTZMNBCZ2DCE6PxjkGqDr-2BnXYxe99f4GHg-3D-3D))

**GLP-1 / obesity, the franchise keeps widening, and Lilly is pulling ahead on breadth.** ADA 2026 was the backdrop for a wave of data: Lilly's tirzepatide (Zepbound/Mounjaro) hit Phase 3 wins in psoriatic arthritis (together-PSA: ACR50 + ≥10% weight loss vs Taltz monotherapy at 36 weeks) and psoriasis (together-PSO), pushing the GIP/GLP-1 into immunology where, per Scrip, "Novo Nordisk has no similar studies underway for its GLP-1 blockbuster, Wegovy." Lilly's oral GLP-1 orforglipron ("Foundio") is in Phase 3 for osteoarthritis pain and stress incontinence. ([Citeline Podcasts](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiQ2xpKMJceGnLpvLMV1q75jNH387i2AoPI2EE1-2BkgW5HEvtOOFBV1R5Gdt8-2Ba87V-2FT9F9nQihXkInZHK69PB4Zny9KItJGWTWYeVtB5ZACIg-3D-3Dzp4Z_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoTFyr-2BLnKOqdQyKb7Qz3hL9WrAfLZPZaZRfuyaNIA7fEurEjKuLTHchmdQhl6NTZyEZWuF6W-2Bnk3hl7MzFih2n7ICxJoAOXPS089oJoBes1rKEsLoFwX9skWtBZl-2FVSWyg-3D-3D)) On efficacy, the clinical shows converged on a rough hierarchy: tirzepatide ~21% weight loss vs semaglutide ~16% head-to-head (SURMOUNT-5); retatrutide (Lilly triple agonist) ~30% over two years in BMI>35; survodutide (Boehringer/Zealand) ~16% with 63% liver-fat reduction; oral orforglipron ~11–12%. ([DoctorPodcasts || Cykiert Files](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg4rUiN8ixZ8-2BrLUkvKxXQS0a6k0dX3mrBl2xuTiWEI0tLNzk-2BbIvv96VhE7kUbBEJKI02QpwnjwnfI-2Bc9rPSHvEDJcruOXtZpcqeNp43cLOw-3D-3DOJ7X_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VobFGSPBeNQFsPHaLAuR5F2TxMHrDTiunwMgH3TY6U2fRX8r5BiUtjw5A4xWH-2BawDxuvvVxRqsrGH2Jvw6CdpTc4Xsd4RCuapPIn16klVC6eLf-2FM3bTKSAJnLPXRsLBrN1w-3D-3D)) ([The Obesity Guide with Matthea Rentea MD](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhoNS0uTv-2BRK6c14wN0ttNWaBYPMVjpNFdU1paW5-2FN7SkPj5FKELjrXQ6UbKmqpDxh943AfLCpykHdGaT0z-2FmaOeBj6nr-2FYMMeqLWHV9gqaYQ-3D-3DKSHA_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VocvdIfHySa4gh-2F7g2w8xSSu1-2BmgvmHxjTs2wna35pYJMiiVATkk4GlonSKpNj6L-2BE-2BsWlZlk9RLD5Ua-2FYowf4JYyr4O1bvxQ9d-2FfQ5BY2fhhYHOMll77yViYjJCwbn7w5A-3D-3D))

**Obesity-drug pricing / access is now a PBM battleground.** CareTalk dissected CVS Caremark restoring Zepbound coverage after reversing a 2025 formulary exclusion that "saved employers money but prompted patient anger and a class action lawsuit." The hosts were blunt on launch pricing: Lilly and Novo "were jamming people on price… charging 70 to 80 percent less in Europe," making the drugs a "budget buster" that PBMs had a fair case to manage. ([CareTalk: Healthcare. Unfiltered.](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhPzhtNoB-2Bqlg7tjm7aUNQFEAgYPZ4bx9JkP2LsTvDMU9FByopomBdJIB8I2d4vLLTwHMmiP2T7tyLjNLHllS0gSdXsWS8yuAQXg3sFizK5mg-3D-3DG4Nc_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoSZK8lEvNYCIh66qqKNZLA3tbfv2f773dkzOWYeAq115QHQ5-2F-2FYGrNRMQjGbRuadNxcAtLpwS5eaIC-2F-2B-2FteKivkCA-2BNTqRYYxBEbWyCRblxCnYfXG-2FlhlQoSng9jcBdDwQ-3D-3D))

**ASCO 2026 oncology readouts, ADCs, bispecifics, CAR-T and pan-RAS were the stars.** A large slate of clinical podcasts (ASCO Daily News, Oncology Brothers, OncLive, Research To Practice, Oncology Today) covered practice-changing data. Standouts with clear commercial owners: Trop2-ADC competition in 1L triple-negative breast cancer (Gilead's sacituzumab govitecan vs AstraZeneca/Daiichi's datopotamab deruxtecan); enfortumab vedotin + pembrolizumab (Astellas/Pfizer + Merck) extending into neoadjuvant bladder; and Revolution Medicines' pan-RAS inhibitor in pancreatic cancer (see Sections 3 and 5). ([ASCO Daily News](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOi78WGVd7EZVMdnliCJaky0aM4UIoVRBZtdhrWv-2FOr0DqYRRMgAbXNcm5KMIr6-2Bq8iq3NXM7zQMod6zVu8J1UehWQEJ3trCND1lZBJl73zXkA-3D-3DGQLc_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoSeMAjRD6QEaxOSl2MTKXuRHFaB1GelKAMEFCOHfZi5uHjGkSgIf61LhZsYAcCDviud9jkgJjSGPY9L8-2FnHVTqlB9xbzCgmVM0VuMubgd3rzDtpAuyqsBfskcDCOq-2Bct6A-3D-3D)) ([Breast Cancer Update](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg-2FLAOgVc8t4jPZwSAoFRN1H3Y0FpaOGrxJsReQuWsPaz8ruGz8Zxb1yAr5qVG1Z2RhCrxO9fTbkGe7yviBPrpp7Q8ooqCuH3HceGMMLlZ4zA-3D-3D9njP_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VodCLaMWQX1WmjuHxj8eXWuskSyD7Ta8twyCBJjVSC4K1ulqRui8rSKuaIM83qJbwQyMkOIZq35ygNWkH2zaJG6Ly0CafWkdypkChYRsjtfqm0N6eHReQGSehOjV-2B3PZOYg-3D-3D))

**AI in drug discovery, real platforms, but the hype is being interrogated.** See the dedicated debate in Section 2. Multiple big pharma are still increasing AI-discovery investments (Cell & Gene), while practitioners flagged hard limits.

**Reshoring / supply-chain re-wiring and the Biosecure Act.** The DoD added WuXi AppTec to the 1260H "Chinese military company" list, which would automatically trigger "biotechnology company of concern" status under the Biosecure Act; WuXi has sued to contest it. ([BioCentury This Week](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgVMFhquD44R1J5rj8fptp-2Fb6UDC4PpVrtCoGaw0Sc6uYa68qj6dDkJqyLIlSXzRczKjNCBxPtmDqH8pxpzIKCS7Mx3zeo4U2ipuzbW0s7WOg-3D-3DsalZ_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoestvoNgeCPPllRk0O8NN4Y3o259ZHopiXrAEJVwNcFoBHf50ClGBKd1ILDXlMdTmrA-2FuiujyLLmqg-2FAC6Y0TqRAMJgc4sZOMaX8j8RxipmQzBM6h2-2BC7tcFFL-2BkleLS4w-3D-3D)) CDMO/manufacturing shows described a shift from hyper-globalized supply chains to onshoring "in the heartland" (Illinois, Indiana, Pennsylvania), one-stop-shop CDMOs, and pre-paying for bioreactor capacity months-to-years ahead. ([Cell & Gene: The Podcast](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjaBjZvdxWeFIWfM7d3z-2BpmvxRj5Z9mHSQU-2Brtabhb-2BcKyNbSA6JVB6p9EyIEwb-2FmaX1M8NnayBz6DRPpc-2BomDo3Yu2DfnCGZCIzCGQxiQrBg-3D-3DQiLQ_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3Vodz8BWwDUXSvil46W4NTK7X4lWYgWNBDProjTiEsO8nISkd-2F62sRORKTq3eukzyVSPSLRGT7qSKDVeL-2B29v8qKWLZoZcSsKCdJzWxz8Vw-2FL9LRWzhGv-2F60FC8V6COOZedQ-3D-3D))

**FDA leadership reset is unlocking stalled programs.** The Readout Loud noted Marty Makary and Vinay Prasad are "no longer at the FDA," and that uniQure's Huntington's gene therapy, earlier deemed to have insufficient data, now has an agreed path to a Q3 BLA submission. ([The Readout Loud](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgEvZiqBJAm67eJczEWQ1lnQ9xc8jHe67fJBzJc19n0oj2-2Fg8RBytAew4NGWI2JOARsy0JhAsZahVflaE8NP9KilLWF6zxXxq7cgsOL8CfznQ-3D-3D7VGS_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoW7ifPqDiBasXWNRwfPJeBaf43sAUCBqqa7MhsSKbBcsLmz-2FLe4Y-2FTv-2Bn7BWU0Lg0mNejfvX0i0hVjvOqffyYmCFnqiG1i3hPpyS-2Fq62t8xNMLBuj9aE2sxDIoLRGCBeew-3D-3D))

## Active Debates

**Is AI in drug discovery real or hype?** This was the week's sharpest two-sided debate.

- **Bull / "it's real and compounding":** Insilico Medicine's Alex Zhavoronkov said the company has "nominated 30 developmental candidates since 2021 (13 in clinical trials, three Phase 2s, one Phase 2 complete)," arguing deep learning has gone through revolutionary step-changes (2013–14 deep learning, 2017 Transformers, and more recently). ([Realities Remixed](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgCfjpedCMi0uQwQMCrn-2FjItkRgKrzXaxCDH1WfF9WJs5BPHrD5Iq6puZ2-2Bmwtrh-2BuRFDPKsxDMyfrVeUctylEdx0y1AbmlHtHp8ajWUfF9Yg-3D-3Dbfqi_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoR-2BCPI6uL7A0h6gHkoZ7zDsYuLMLr6WxgFCYRzh0oojd-2ByB4bTyiVUaKUZ4pgewGeDR96mNXpTnwQS52AVLxksp9mlytwWilcWV3BSQL1XtOKuskU22maaAOqmwOtqgcDg-3D-3D)) Regeneron described AI as "core" to discovery for years, sifting "hundreds of millions of variants" from millions of sequenced genomes, paired with proteomic + clinical data, to pick higher-conviction targets. ([The Bio Report](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgLPmlZH8TgEHEjhvXed3E2LTJfUn4p-2FPYXoHBUsClDdr2UBTjjuceuzlzpRJfiXDZo84IG2ZwfV5eamEcDG-2FQUnIB05FeN-2BwRP1cj9mLL3sw-3D-3DkCyx_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoRTrU9RAZE2rbp76Ofwbj-2FZe-2Bf5-2FbLodct6tW-2F7Kxlq25J0wHGgLeY8zG6KuhGnu9tJ3Zg7PKShy-2B5PgNHiqGKnFWcXI-2FUuTNWh-2FiOX8jUk3wtatMt5Lr-2B4NQeiu5gZEeg-3D-3D))
- **Bear / "most of it fails on fundamentals":** Data in Biotech argued generative models routinely propose molecules that "cannot reasonably be made," because they rely on abstract 2D string representations rather than real 3D molecule-protein interactions, so predictions "very frequently don't pan out when you test them." The fix is constraining the search to synthesizable chemistry up front. ([Data in Biotech](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgUjZITxavLYnpy7ySf4xcvMJwRtPqkirTjhouLwmSPJ8T4-2FooYcyn7NJssLP9VCy6rCVRYxRLw56kI7JUXUX3GD7ynTczH6rTM5nhWCW525w-3D-3DBRc3_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VodUP54f6ee2vWTLSV6cLwnhUSpTZ8xCFUYBdr7zn-2F-2BIkfAzf0A-2Bn6sW0dD4zsRS-2BxcFgAB3C8UeMJgLShVx3kGowBG6dcPn4r85IjswsZXK3GhMzSyHTKaQIWwerrWagXQ-3D-3D)) AI For Pharma Growth put a number on it: "80-85% of pharma AI projects will fail because they lack proper data infrastructure underneath their models." ([AI For Pharma Growth](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOh0-2FRYbFQR77WDtJfzSG38YYsXaJ4x4axGADyES6JVpGer-2BhNOS6u00T4zNJKYtx6GIHLqIlafBSaoY865H31XNypeMUPY-2F49He-2B1OGmcHZbA-3D-3D5Y69_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoVDKHZBwGAMUgkB9oH3PmDLT-2BE3YYqY4dBmCRJVI9EQa-2BO6FnnzTVpMKWXO1MA-2FBmn31Rt62I1r6oLUDsQovJ1ugeTsYbimRZd5TBCRrSgP7EgtrbLtpPGdJQbO4MeO8dQ-3D-3D))

**Has biotech bottomed / is this a "bubble" forming?** Value Hive's guest Peter Mantas argued we are early in what could be "the most real biotech bubble we've seen in a long time," born of pessimism, not froth, but cautioned the setup isn't complete: "You don't even have an FDA head right now… NIH is seeing budget cuts… you still have walls of worry." He stressed biotech "doesn't need rates to go to zero," just "stable rates… come down and kind of stay flat." ([Value Hive Podcast](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgBu8Zkz9uMlRmMo-2FwUEjic7GFi4tWVHzNqX2LtPz-2BdJvldGiD50tvK-2FaXMZ3Lrf-2F07QCTaKR4E4RnOUI59F2r01-2BErL-2BqATekWoitmSOSXFw-3D-3DcODz_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoSQbNeerVMVRNzzL1ZzKWDKWQpG0fngk1cgXpZAoBiS7HT-2FI2cp5LX8l9CFMXp0F4PSaZEWc8ez-2B01QgK6VGKPHSyrDXKN42DP6d4EpfR-2F1dGrMggzoyr5fFVp6YCpOPFA-3D-3D)) UBS's Yee was more unequivocally constructive, "We think biotech is back." ([CNBC's "Fast Money"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhIPVwR8Xv9q9VvJzigGgivq1lsuu5hKeSuKWNhCmsNDegQlyTH4TtHpai-2F3PhjXtzdk-2BGBg21E2Sej1ZWmbi1B0Q8-2FmXdBb9WeAxMhjxvnXQ-3D-3Dulki_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VofSk2-2Bpmifvg1KiML5YrpsqMA45LVj1XB50m3uinkxC-2BsjGfTSQptp3mDOGIJ9VrUCxn0TuLYuD1zibcBACC5XgQJIFm6fn72qqnE1zJMey16okeeiYdS0IkFMwfUytHkA-3D-3D))

**Did PBMs overreach or under-embrace GLP-1s?** CareTalk hosts split: one argued CVS Caremark was right to manage an "extortionate"-priced "budget buster," the other that the real miss was not embracing "remarkable drugs." ([CareTalk: Healthcare. Unfiltered.](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhPzhtNoB-2Bqlg7tjm7aUNQFEAgYPZ4bx9JkP2LsTvDMU9FByopomBdJIB8I2d4vLLTwHMmiP2T7tyLjNLHllS0gSdXsWS8yuAQXg3sFizK5mg-3D-3D3XiU_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3Vod4tRS9xEA-2BcJPKSrIqne5y0lV5xXkV9yERakZQZ79we1yOo4Fnm6anDQITZlldwGP7CfVQlzWK-2FiaNzPuAyMRvlACeNfAfh1m-2Fi3s-2BVx2J5wAOAM7RoGqgZ-2Bnoi1uvWzQ-3D-3D))

**Lilly vs Novo on obesity breadth.** The implicit debate across GLP-1 episodes: Lilly is widening into immunology (PsA, psoriasis), osteoarthritis pain, and incontinence and "did three deals on a Tuesday," while Novo has concentrated semaglutide on CVRM (CKD, MASH). Scrip framed Lilly's autoimmune push as a structural advantage Novo currently lacks. ([Citeline Podcasts](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiQ2xpKMJceGnLpvLMV1q75jNH387i2AoPI2EE1-2BkgW5HEvtOOFBV1R5Gdt8-2Ba87V-2FT9F9nQihXkInZHK69PB4Zny9KItJGWTWYeVtB5ZACIg-3D-3DJafK_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoTc-2FuIV88eOIcLqgv-2BcUV2sVYG7G-2FyoMzC-2FckORoibA82KSgoazbhNJAAzkEw60oAKMl6lpuVq7n8BWCDkw8anj-2B4hkJ3EAXNpDzCLOMYNvovk-2BpgFxT-2Fd4k7HrJNvownA-3D-3D))

**Oral vs injectable GLP-1.** BNY's Double Take flagged the adherence problem, "80%+ of users discontinue within the first year," as the core case for oral formulations and "off-ramping" strategies, even as orals show somewhat lower peak efficacy than injectables. ([Double Take By BNY Investments Newton](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOj0pyHZtyN5kFT6iKpx-2B4iNE2yZ1qBZ5ti8f6Mg-2By80NZpD10d-2BSoLZf9xK4gqXPVksnVuGd56UrTHUUEQVHyfFL5TVM59M4UpPReipTeBnig-3D-3Dz9SR_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VofPrn4mH6r1UCglWEVG-2FdEEYclkPTpHTDhy9-2FfdQZUcjCQQVlY3E7O-2BCnKi7n1ahbSZZZY2rymt93mM-2BFFHcBZ9sa32rv-2BJifDiy4KHnIzx0Wn0FHt1XFWFXkCL20AR-2B4A-3D-3D))

**China threat, existential or manageable?** BioCentury treated the WuXi/Biosecure escalation as a live legal and supply-chain risk (companies that depend on WuXi services are also exposed), while Mantas called China "really exhilarating" as a source of competitive pressure that the US is "starting to get more serious about… but they're not there yet." ([BioCentury This Week](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgVMFhquD44R1J5rj8fptp-2Fb6UDC4PpVrtCoGaw0Sc6uYa68qj6dDkJqyLIlSXzRczKjNCBxPtmDqH8pxpzIKCS7Mx3zeo4U2ipuzbW0s7WOg-3D-3Dhxc3_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoVpUbeucp20l-2B0Bk-2BfXjawQPwWTEhzYemB8cCfwMhQcFU72j9V7PqxIPW9jG5uCEJLcWjBEk3meUIZzzK4QRJbnPysxQEXLNs75odS0nZzuYnyLQjlAATtkh9DXToPwX4A-3D-3D)) ([Value Hive Podcast](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgBu8Zkz9uMlRmMo-2FwUEjic7GFi4tWVHzNqX2LtPz-2BdJvldGiD50tvK-2FaXMZ3Lrf-2F07QCTaKR4E4RnOUI59F2r01-2BErL-2BqATekWoitmSOSXFw-3D-3De_mO_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoZSFWd0q1uoyaJv7VyvvWKOi7-2FMwq7381AM831CQmDLiaHLS9sSrE36s0SFxMsE3y22dzyDA4yupWpaHR7webPZuEOFDk6FCwQ-2F4XmgKEdzoky8USNXG4Nk-2Brtm2ROd-2F-2Fw-3D-3D))

## Stock-by-Stock Bull / Bear

Most named-stock investment commentary came from CNBC Fast Money (UBS's Yee). The oncology/GLP-1 clinical shows are not investor-facing, they name drugs and sponsors but do not articulate stock theses; those are flagged as clinical.

**Merck (MRK), UBS's top idea.** *Bull:* "a real turnaround situation"; trades at 12x earnings, "string of pearls" M&A (5–6 deals, each <$10B, mostly de-risked) projected to add "$20, $25 billion over the next few years" to replace most of the Keytruda cliff. Yee sees re-rating to "14, 15 times… about $140, $150." Analogy to AbbVie/Amgen "growing through" their cliffs. *Bear:* the well-known Keytruda patent cliff (~$25–35B) "makes everybody scared." ([CNBC's "Fast Money"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhIPVwR8Xv9q9VvJzigGgivq1lsuu5hKeSuKWNhCmsNDegQlyTH4TtHpai-2F3PhjXtzdk-2BGBg21E2Sej1ZWmbi1B0Q8-2FmXdBb9WeAxMhjxvnXQ-3D-3D7nOq_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoSNQQSJPaGP8hZhoXVTKtugZwsI-2F9ucu-2FY9SA4K2H0ue46XVcAyyRMjBg3vXj2l0qo6SttkNNKhdTuiZ6PuoOJ0sBRKCG6Gp7Y513hudNu7fDNjwAvFnqkyFcAkjlwoPGw-3D-3D))

**Vertex (VRTX).** *Bull:* "down 50 points year-to-date… poised to move back to the upside, $500" in 2H; Yee thinks competitor cystic-fibrosis-drug fears are overdone, "not going to be a big deal." *Bear:* CF competitive concern is the overhang weighing on the stock. ([CNBC's "Fast Money"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhIPVwR8Xv9q9VvJzigGgivq1lsuu5hKeSuKWNhCmsNDegQlyTH4TtHpai-2F3PhjXtzdk-2BGBg21E2Sej1ZWmbi1B0Q8-2FmXdBb9WeAxMhjxvnXQ-3D-3DXuWw_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3Vof9agpMALVMCVesLLJY-2FhA0b1QeJAqAzgl-2FmMwB9NrqztoX-2B-2Fb4-2B-2BrlI8Hbz7I6AtUkwLzWhOagO2brqDjnn5UDzj33LcZ3-2FTeeogD5PXdl1aFOVPQEFH8Hvougq4itpaw-3D-3D))

**Eli Lilly (LLY).** *Bull:* "the hottest dealmaker in industry" (BioSpace) with "the biggest balance sheet… all the money you can do", "did three deals on a Tuesday… just bought Sintessa" (Yee); widening obesity franchise into immunology/pain/incontinence; tirzepatide remains the efficacy leader (~21% vs ~16%). *Bear:* none articulated this week; valuation/expectations are the implicit risk. ([CNBC's "Fast Money"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhIPVwR8Xv9q9VvJzigGgivq1lsuu5hKeSuKWNhCmsNDegQlyTH4TtHpai-2F3PhjXtzdk-2BGBg21E2Sej1ZWmbi1B0Q8-2FmXdBb9WeAxMhjxvnXQ-3D-3D5eoD_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoYNA-2FxNAsyf92-2Bmp5GWSr2VF3NCSIlcYUXJzIaC9OEKU-2FgdbuGQIUulYqZa1MPtFX0Je5Ei4UfnBnzC7h6witE4VqcJCivkNRBYNH36xpDSWxNbLXvhhuczDJmPP4gg0BA-3D-3D)) ([BioSpace](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhGK10zWSnZ6E203Y4PdPEh20On5uA3FObqi2TTX0U-2BfHP0uBBsNoMdEWmuSkimuhB57Gas6MGQUpWmuOnwMCg9ByQZIV-2B-2FVybvEKkVMFRdvw-3D-3DK8fo_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoUhPZ-2FgbtCZlUr941I15s9puVwdbKuXIFZETNxDOEY0JgXkkP-2FR3ln7KAAEaR4v4s5QC79FK0dEVb0Z-2BK8ch-2BUdyTDwjP86zk4zA8QJh1KNxKoWoZUef8kVR5uzATNzbjw-3D-3D)) ([Citeline Podcasts](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiQ2xpKMJceGnLpvLMV1q75jNH387i2AoPI2EE1-2BkgW5HEvtOOFBV1R5Gdt8-2Ba87V-2FT9F9nQihXkInZHK69PB4Zny9KItJGWTWYeVtB5ZACIg-3D-3DDhPV_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VodnUE6VyOJwVpWWyG75Rdgw6uzK6Vgz-2BmaNiFrKQ4VmIuzmSKuFj8CkbU6fx4Kdn-2FthIf2xNxPQ9HaGjqCa-2FFLWLnOqK-2FIj26b6M3o2FujP2sR4AReVUd668pDoih0oNWg-3D-3D))

**Pfizer (PFE), used as the cautionary counter-example.** *Bear:* "Pfizer spent $40 billion to get past their COVID windfall. And the stock's been punished", "basically fully levered. Can't do a lot." Yee explicitly contrasted PFE's one big deal vs Merck's diversified string-of-pearls. ([CNBC's "Fast Money"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhIPVwR8Xv9q9VvJzigGgivq1lsuu5hKeSuKWNhCmsNDegQlyTH4TtHpai-2F3PhjXtzdk-2BGBg21E2Sej1ZWmbi1B0Q8-2FmXdBb9WeAxMhjxvnXQ-3D-3D0A4C_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoeE9ZuRi8oRPY2dibQpu-2FfX83q5Tldmkv5l-2FyhmnABZfm0yeohPYUj5RPfIhFhW1NzE1BZSSWq5HcKy1uKkXNPyZIht8G-2F3ElHhTS44a1jwCZGmOf7Y1UO0ul1dKEhMLRw-3D-3D))

**Amgen (AMGN) / AbbVie (ABBV).** Cited as proof that large caps "grow through" patent cliffs and "go higher"; Yee expects AbbVie ("Avi") to "do some more deals" and "Amgen's got to do some deals." ([CNBC's "Fast Money"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhIPVwR8Xv9q9VvJzigGgivq1lsuu5hKeSuKWNhCmsNDegQlyTH4TtHpai-2F3PhjXtzdk-2BGBg21E2Sej1ZWmbi1B0Q8-2FmXdBb9WeAxMhjxvnXQ-3D-3Dx2hO_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoXtgasnefJOwuVctlByWhCrflJIA-2BpyJkaslF1YBcabYW4GqYREFdX1NJahZFip6kRO65QTi5xFPPoV8kFpxmtxod3jRRJ4pzc8OtusbOD-2Ff7XbXfogwmOMPvVHd9qdxFA-3D-3D))

**AstraZeneca (AZN).** Building a unified CVRM "franchise" (Ambition 2030: 20 new medicines by 2030; Baxdrostat/"Baxfendi" was the 10th); oral GLP-1 "L-Ecoglipron" (licensed from China's Eccogene) in Phase 3; oral PCSK9 in Phase 3. On the oncology side, AZN/Daiichi's datopotamab deruxtecan is a leading Trop2-ADC contender in TNBC. ([Citeline Podcasts](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiQ2xpKMJceGnLpvLMV1q75jNH387i2AoPI2EE1-2BkgW5HEvtOOFBV1R5Gdt8-2Ba87V-2FT9F9nQihXkInZHK69PB4Zny9KItJGWTWYeVtB5ZACIg-3D-3Dsx9p_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VocsgBE6-2BgG1OX7-2Bf90jaWCDrlCFk1ZtRdsyh-2FukF48LyEDk6YXrdSgk-2B-2B3AbrI9CovwMv8wfu59c2tEenSfuWiYvzrt120k2qY-2Bn-2F2qWkf1Zii7Yd-2F-2BWFXGF9-2Fsp8AjG8A-3D-3D)) ([Breast Cancer Update](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg-2FLAOgVc8t4jPZwSAoFRN1H3Y0FpaOGrxJsReQuWsPaz8ruGz8Zxb1yAr5qVG1Z2RhCrxO9fTbkGe7yviBPrpp7Q8ooqCuH3HceGMMLlZ4zA-3D-3DaNAc_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoYUVkVJi4UdSRoReWe4SYhPKaNLM5DFweahbIpMyogC61NGi8MF5Ba8Rq6-2Bk5-2F7bjXrnMHCzoKKXADsOfORDHhCD3QQ2Si7b9kXK29bI57FaRr3A5WKw5IvqQdvHhE1vhg-3D-3D))

**Moderna (MRNA).** Catalyst: FDA advisory committee (June 18) on its mRNA flu vaccine after February's refuse-to-file letter and subsequent reversal; two-pronged strategy (standard approval for 50–64, accelerated for 65+) with a confirmatory Phase 4 commitment; described as a "$1 billion revenue opportunity critical to Moderna's goal of breaking even by 2028." FDA appeared "aligned toward potential approval." ([BioSpace](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhGK10zWSnZ6E203Y4PdPEh20On5uA3FObqi2TTX0U-2BfHP0uBBsNoMdEWmuSkimuhB57Gas6MGQUpWmuOnwMCg9ByQZIV-2B-2FVybvEKkVMFRdvw-3D-3DLF4-_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3Vobh3aWvX4R1-2FE0FOkAPiaSMw0RQjOtxZM1eiNsUZbFkp5DiyAuscU81NA226M9cbwN3tsY5V2n73x8cabjyaCw9PwLC75dMNHWrk4M5bsMDQt5gbVdeWylL-2BEmhY0NDuMw-3D-3D))

**Gilead (GILD).** Sacituzumab govitecan (Trodelvy) showed PFS advantage (HR ~0.62) in 1L TNBC (ASCENT-3) and HR ~0.65 with pembrolizumab (ASCENT-4); clinical framing only. Gilead/Kite also cited >75,000 patients treated and >34,000 on its CAR-T portfolio. ([Breast Cancer Update](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg-2FLAOgVc8t4jPZwSAoFRN1H3Y0FpaOGrxJsReQuWsPaz8ruGz8Zxb1yAr5qVG1Z2RhCrxO9fTbkGe7yviBPrpp7Q8ooqCuH3HceGMMLlZ4zA-3D-3DIBO2_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoZPqqnzjjBTbBccP8nQktf2utoz4l-2FYaNdtJvLFEgi1VH7o8KWjbjscjOjRIWGmYiGiZn-2BjgPlRsCc5nTd-2F6IPkuPjr3-2FHzh6qehnRyR44WmcykItV747L8UI0fKJT5xoA-3D-3D)) ([The Readout Loud](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgEvZiqBJAm67eJczEWQ1lnQ9xc8jHe67fJBzJc19n0oj2-2Fg8RBytAew4NGWI2JOARsy0JhAsZahVflaE8NP9KilLWF6zxXxq7cgsOL8CfznQ-3D-3DWwQN_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoaURFElNcgYVIA1nsGb42FIa038g54zfgEonDY4GTRZ0DaEu-2BhQgyKLDPQT3HKJ9CasGhkugJbeS90PsBbHPtUcKcwRefomj2xduDkLMmAhOvcI1U-2BfIjJ1l563jNNZpNg-3D-3D))

**Regeneron (REGN).** Profiled as an AI/human-genetics platform leader, claims target selection yielding "4–5x higher clinical success rates" vs ~10% industry approval rates, and made a $75M concurrent investment alongside a biotech IPO this week. ([The Bio Report](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgLPmlZH8TgEHEjhvXed3E2LTJfUn4p-2FPYXoHBUsClDdr2UBTjjuceuzlzpRJfiXDZo84IG2ZwfV5eamEcDG-2FQUnIB05FeN-2BwRP1cj9mLL3sw-3D-3D9kNA_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoTdziKjiI5WrxORW5O8TEXyx-2BmqqjBelZ0y5R9ae1Ple-2FT9PitrVeN5Tt19GFWaekNbnVGqXVitKhjqwCmJKV1N76E5LpXtj7D4GHnWjTNBL4kokk2haG3XurcehnB6-2BRA-3D-3D)) ([BioCentury This Week](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgVMFhquD44R1J5rj8fptp-2Fb6UDC4PpVrtCoGaw0Sc6uYa68qj6dDkJqyLIlSXzRczKjNCBxPtmDqH8pxpzIKCS7Mx3zeo4U2ipuzbW0s7WOg-3D-3DG6k7_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoVHzDUVnrmGplVyn74B8T4wotTGhlD1K2hFLOzZt-2FJcJ6w4yCVa7iOERfzSO9FFriouzZ9JbaC4WR2sebRrDkzIpgOMkwmA0gmFQapWnegNeFKS5KIUWiitgDTXMFdpfjg-3D-3D))

**GSK.** Scaling oncology ambitions via a Nuvalent deal/partnership (cited in Scrip's roundup). ([Citeline Podcasts](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiQ2xpKMJceGnLpvLMV1q75jNH387i2AoPI2EE1-2BkgW5HEvtOOFBV1R5Gdt8-2Ba87V-2FT9F9nQihXkInZHK69PB4Zny9KItJGWTWYeVtB5ZACIg-3D-3DR88U_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoeFIj22CvHlJt2kUWqXQ6EtQIeWVZ0AAkIp6LY8xQSRg7HNzZKmyMkFZZ-2F0MbJGy7OfLsiCaCrBXNjU7JWt15l4fZQKXnvGf7-2Bt8urVXEj0ECSt82LSemC9unuxRCQuPFw-3D-3D))

**UBS named potential takeout targets (small/mid biotech).** Apogee Therapeutics (APGE), Phase 3 atopic dermatitis drug; Cogent, "on file with two drugs to the FDA"; NBX, Phase 3 rare disease + an obesity drug "getting a lot of attention." Yee: "These are not big transactions. A couple billion dollars here and there, string of pearls." ([CNBC's "Fast Money"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhIPVwR8Xv9q9VvJzigGgivq1lsuu5hKeSuKWNhCmsNDegQlyTH4TtHpai-2F3PhjXtzdk-2BGBg21E2Sej1ZWmbi1B0Q8-2FmXdBb9WeAxMhjxvnXQ-3D-3D6T6b_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoWLBy5r3t6TgcuAcoFZUS5FNi3DaLEN0Set57AaYvFr-2BSAtV8qx8tar0m-2FaNYMqtrxFUwcCovm13nrtsqR7z-2FjeK6XhYirW40HgM4NiZSNwGfE9yzUfZ28BnJraj9PG0wA-3D-3D))

**uniQure, Huntington's gene therapy.** Agreed FDA path to a Q3 BLA submission; pivotal-relevant data showed disease progression slowed "by 75% after three years," meaningful in a market with only symptomatic options today. (Clinical/regulatory framing; STAT reporters, no stock call.) ([The Readout Loud](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgEvZiqBJAm67eJczEWQ1lnQ9xc8jHe67fJBzJc19n0oj2-2Fg8RBytAew4NGWI2JOARsy0JhAsZahVflaE8NP9KilLWF6zxXxq7cgsOL8CfznQ-3D-3DGvC7_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoZOWGsIQFDICzHV37L-2BcvRyXDM53h4F6g-2BPn8N-2FvHUuCiYCC3wPm-2Fs3RKjDZWYNSEXp7K3pbZZOISx6rSOO1jBFi7f2iQAd5D33oXHUndUHiFenpV9Pe62-2BG2TvpTUBTZg-3D-3D))

**Revolution Medicines (pan-RAS).** Daraxonrasib (RMC-6236) in previously-treated pancreatic cancer: RASALUT-302 reportedly met endpoints with OS 13.2 vs ~6.5–6.7 months on chemo (HR ~0.4), heading to an ASCO plenary; single-agent frontline ORR ~50% at AACR. A genuinely high-impact catalyst, discussed on clinical shows (no explicit stock thesis). ([Research To Practice | Oncology Videos](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOghUHAekUm80Ooh7ohMd8QXE9NpbcQGrxTZHvb7iYx8Eu5fTKjP89HSfC-2F7VGPt66EAYTdDyFqCfpv80TGhln3AEiMcSS-2BUAymhTsy7Q40qQA-3D-3Dwoim_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoZwUHS8VJj5VAADJ9rJFdiem2dytJ0v4saPbfQx2EtpNsLFEhGqM2LhnM86KpPEnP2RUTs3OrGC7zM5KdNxbnu9UOkUKKKa4lLt1-2Fd1cDsLU8Ax2endeO9bnkJ0R0ojv-2Fw-3D-3D)) ([OncLive® On Air](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjnjl0OdmAarmULgj6MQeFUokpwKaA-2Bw1wUgl072QocYASZ3abnZ-2FoUhOkXSd1cS9XXpaSM5YLd0xMdcWaUt-2FHeE1WjB-2Fxbu6dNYcU4MZxIDQ-3D-3DlKLT_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoWUmgAgHiJ-2BkilNa7rHyfQuzN1ft6ZY1-2FwEdojfN-2FAeEHFBSiscLzZWiuynnOCAWhQiVjpb2HLmt1SGaoejNdh-2BhSWQTapIEW7KCUyqTIBz83NUg7SFFYqHH9WXla5xOgA-3D-3D))

**Zealand Pharma (ZEAL) / Boehringer.** Survodutide (GLP-1/glucagon) showed ~16% weight loss with 63% liver-fat reduction (Synchronize-1), relevant to the MASH/obesity thesis. ([DoctorPodcasts || Cykiert Files](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg4rUiN8ixZ8-2BrLUkvKxXQS0a6k0dX3mrBl2xuTiWEI0tLNzk-2BbIvv96VhE7kUbBEJKI02QpwnjwnfI-2Bc9rPSHvEDJcruOXtZpcqeNp43cLOw-3D-3DNmhd_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3Voc1LT6OpA5Nts4laKPAKcWxdinboJxit5UuDdbqIAl-2BERFrTTVUgk5tFpOiJrkOzbcSse3PX3-2BEYl8WfO1rNdUBJBxlNHwzrURRqPPpXNOR7PhMv0y-2BM41-2B2MbHu4x5n6g-3D-3D)) ([On The Pen GLP-1 News](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhkp9AGVkVfysq8OaJeqXYcitJEHJIf69XE3psxMhBlcIT5-2BWcoS6bLDZbdK9soK1YsjY1HjRdv0lm0NlVvPnF3EXX7D3BP5-2BZFziEoJREhJQ-3D-3DiJLE_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VofDkEoSuMkPO43WIH-2FOJ7qDOzrzUr16irPh-2FK4ndYEu8v2Icjgbwg-2Bc-2BkZuGDtdFPLhIbrt-2BhFUgKKesWxHWXA9lDHUIsoeM1bjVspECvlNfmrxmpu6n5ii6wVw2HoE-2Frw-3D-3D))

**Not mentioned with investor commentary this week:** JNJ, BMY (named only as a patent-cliff example), NVS, RHHBY/Roche (orforglipron via Roche's "Fundeo" branding appeared clinically), SNY, BIIB, BNTX (BioNTech's B7H3 ADC appeared clinically in prostate), and the tools/CRO/medtech complex (DHR, TMO, A, IQV, ICLR, CRL, ISRG, MDT, BSX, EW).

## Notable Quotes

- "The resurgence is multi-year… the surge is being driven by a lot of M&A. There's record M&A numbers. Pharma's face the biggest patent cliffs that they've had ever." Michael Yee, UBS, ([CNBC's "Fast Money"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhIPVwR8Xv9q9VvJzigGgivq1lsuu5hKeSuKWNhCmsNDegQlyTH4TtHpai-2F3PhjXtzdk-2BGBg21E2Sej1ZWmbi1B0Q8-2FmXdBb9WeAxMhjxvnXQ-3D-3DL0u8_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoZGo6d-2FiyCJq4DOWyLT6vUBFFCVEnQ2a9bagd9g8TIePfuIdmLqcsgQFAhwfBhp-2BlfCOH9b2t359Xg8jJBNKCQSezXhwBFMuCRvw7mNB7rwQEjbAEtMyDBgPl-2Bud8oMUBQ-3D-3D))
- On Merck: "Stock is cheap. Trades it 12 times. I see that stock breaking out. Could get 14, 15 times… about $140, $150." Michael Yee, UBS, ([CNBC's "Fast Money"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhIPVwR8Xv9q9VvJzigGgivq1lsuu5hKeSuKWNhCmsNDegQlyTH4TtHpai-2F3PhjXtzdk-2BGBg21E2Sej1ZWmbi1B0Q8-2FmXdBb9WeAxMhjxvnXQ-3D-3DVthc_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoTnjuMTUo32zDYS-2F-2Bt-2FkZP8-2FxmHiox0c2OTKk4yf0RYOh-2BR6aoTH93zy5DbfCVLEhDQSqT43NdV9Ltx3qbSgVS51iUp57TtUBKOP-2FL1gtUzC91VaE8AL74d601ZuzcmVnA-3D-3D))
- On Pfizer: "Pfizer spent $40 billion to get past their COVID windfall. And the stock's been punished… basically fully levered. Can't do a lot." Michael Yee, UBS, ([CNBC's "Fast Money"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhIPVwR8Xv9q9VvJzigGgivq1lsuu5hKeSuKWNhCmsNDegQlyTH4TtHpai-2F3PhjXtzdk-2BGBg21E2Sej1ZWmbi1B0Q8-2FmXdBb9WeAxMhjxvnXQ-3D-3DNSB1_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoWrfarvtlLydVLFtoOK-2B8JXffjGj1McxffxskECmGERe-2Bi-2FhKFCVdsc4OgS6cHBqtxbIvVprzI9JksYsiNurXXWFl0Mj5o1fWlJPD2p5yNW8JDC84TAETghzYUHFmQaF6g-3D-3D))
- "Bubbles are born on the darkest days… I think we'll see the most real biotech bubble that we've seen in a long time." Peter Mantas, ([Value Hive Podcast](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgBu8Zkz9uMlRmMo-2FwUEjic7GFi4tWVHzNqX2LtPz-2BdJvldGiD50tvK-2FaXMZ3Lrf-2F07QCTaKR4E4RnOUI59F2r01-2BErL-2BqATekWoitmSOSXFw-3D-3DYVJB_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoTzVV3jADw7zbL8xhIWUjJsrJLxF2Td5SGSt0-2FRfZ7gMd8vMGfhspKm7rEOXZFJb4A5h2fCVkIDktIjPfO4hN25JMGbIlzVuJqSrszOftyghV2eZnJ4al-2FYxF9mOlGduRA-3D-3D))
- "You don't even have an FDA head right now… NIH is seeing budget cuts… you still have walls of worry." Peter Mantas, ([Value Hive Podcast](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgBu8Zkz9uMlRmMo-2FwUEjic7GFi4tWVHzNqX2LtPz-2BdJvldGiD50tvK-2FaXMZ3Lrf-2F07QCTaKR4E4RnOUI59F2r01-2BErL-2BqATekWoitmSOSXFw-3D-3D-GY2_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoXL4mqzK-2B68iuSJlhjGTEvwQ3xuPSGp1JKUly-2FSnDhb69Lb6DrUcjzztnGzHJxAREde6mbYt1e-2Bs5WRRiOe4kRKU9udUIFBG-2BCFTfjRkOm4AbREWXqQkAk4iky2nNuQp6g-3D-3D))
- "80-85% of pharma AI projects will fail because they lack proper data infrastructure underneath their models." ([AI For Pharma Growth](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOh0-2FRYbFQR77WDtJfzSG38YYsXaJ4x4axGADyES6JVpGer-2BhNOS6u00T4zNJKYtx6GIHLqIlafBSaoY865H31XNypeMUPY-2F49He-2B1OGmcHZbA-3D-3D7ILQ_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VodH-2Fb8lLcLxl6xfDCye-2BeZDEpcpFtMdYtXFpv39K7Eoi6iSFDBdE0zgrsnMXui-2FRx8NdBi2gTy3P1E928LmghIvN4UtUmWiQK3OnodeMBnus4xXnfKe5bveTVsrWu7wpyA-3D-3D))
- On generative chemistry: AI often yields molecules that "cannot reasonably be made… predictions that very frequently don't pan out when you test them in the real world." ([Data in Biotech](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgUjZITxavLYnpy7ySf4xcvMJwRtPqkirTjhouLwmSPJ8T4-2FooYcyn7NJssLP9VCy6rCVRYxRLw56kI7JUXUX3GD7ynTczH6rTM5nhWCW525w-3D-3Dys-8_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoVhuAfYFyhLNUO5PSAqiQ6SD7Hd3sBXnCxPn1jzjCpE0ZfUJZY-2BVN-2Ft-2BRUjaQqGAQdvh9jBnVN-2Fg9d2J8S7L6hZ8GYXGZcQF6Sb6xJCGG8IzpITVeZmNzONsXdFtx3kuOQ-3D-3D))
- On GLP-1 pricing: Lilly and Novo "were jamming people on price… charging 70 to 80 percent less in Europe… a budget buster." ([CareTalk: Healthcare. Unfiltered.](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhPzhtNoB-2Bqlg7tjm7aUNQFEAgYPZ4bx9JkP2LsTvDMU9FByopomBdJIB8I2d4vLLTwHMmiP2T7tyLjNLHllS0gSdXsWS8yuAQXg3sFizK5mg-3D-3DZAcg_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoTLCnKGD0yfX4oEYDhoBEoMm4B30X4NslD03il3dVZLL-2FJSxjYQ19r4IXQB-2Bx3gzu0An-2BPNkIS7QUimsfOJ1zf8yHXMve-2Fvl8nyi9blM9yiTd9Tl4JA-2Bl6kGz60KTH6Zzg-3D-3D))
- On the IRA + MFN + EU JCA convergence: "It's almost like an acceleration of climate change for the pharma industry… seismic effect… irreversible impacts." Steve Mather, Lumanity, ([Outcomes Rocket](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOi24itfKMkA8KVAk2YCqUqrVbv3bOm6rKBdIF7bB19cqOMAzRdq-2FiIRYcTklyw3cw-2BDJd8IU-2FHMxY4gGHvFC2nAV3YwdOvhkjZZJ0q4KlcXlg-3D-3DakD3_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3Vody84Z0kRT9DvFXmY-2BQSXxhzO8ajH-2F4ZjOJwCEKBfOQ7uWeKaqldaHNlwAqWCM8PpNJCe-2FOCAUmhUMlXc0nig-2BLULaBwepRnEl3zds8LcQeV0tH6zVIHEI2-2BbgK9Q-2FHsUQ-3D-3D))
- On uniQure's Huntington's path: "We finally have people at the FDA who are listening… one step closer to this being a reality for patients." Lauren Holder, HD advocate, ([The Readout Loud](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgEvZiqBJAm67eJczEWQ1lnQ9xc8jHe67fJBzJc19n0oj2-2Fg8RBytAew4NGWI2JOARsy0JhAsZahVflaE8NP9KilLWF6zxXxq7cgsOL8CfznQ-3D-3DMB5j_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoaAT0ljCrV-2F-2B23FFq6epYyfAzZYwKjtON8AobYMJ-2Bevy3Qmugef-2FHoJKuYujVprTQyb3Ujb5CyUfj-2BZa-2Bv-2FC54-2FnLiTiqyTm-2BUiqeoHgHpAvlwvFH1iHaBAGWhkBJWXObA-3D-3D))

## Catalysts to Watch

- **Moderna (MRNA) mRNA flu vaccine**, FDA adcomm held June 18; PDUFA decision date in August 2026. ~$1B revenue opportunity tied to 2028 breakeven goal. ([BioSpace](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhGK10zWSnZ6E203Y4PdPEh20On5uA3FObqi2TTX0U-2BfHP0uBBsNoMdEWmuSkimuhB57Gas6MGQUpWmuOnwMCg9ByQZIV-2B-2FVybvEKkVMFRdvw-3D-3DYpNN_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoQMtz98T5HF2AdQfP7nCdQFum-2BSRlXmcG8T7MXeyANbrZdLAAQcu7e-2FbM-2FBZAL-2FW-2BNLmatPHp4LaOr77Fe094AyUMkdemZgT-2F-2FOcdqicN6WuDb-2FQlRlERhF-2Fzry1UYqxzw-3D-3D))
- **uniQure Huntington's gene therapy**, BLA submission expected Q3 2026 following the new FDA agreement. ([The Readout Loud](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgEvZiqBJAm67eJczEWQ1lnQ9xc8jHe67fJBzJc19n0oj2-2Fg8RBytAew4NGWI2JOARsy0JhAsZahVflaE8NP9KilLWF6zxXxq7cgsOL8CfznQ-3D-3D_Mi3_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoQ-2B2aw53MycjVzmBC2wtZzPJa-2BC-2Fp741PSCpN-2BZQOLf4LAIcAnr8Qy8xivKqq4s2V-2FVhRhfUzN3-2Bkwp8aH0LhALnKXsbeOo5UaeZbGzLzshD3RmxjVXFX3vi8dzMHKx-2FSw-3D-3D))
- **Revolution Medicines daraxonrasib (RMC-6236) pancreatic**, ASCO plenary presentation of RASALUT-302 (OS 13.2 vs ~6.5 mo, HR ~0.4) anticipated within weeks of the episode. ([Research To Practice | Oncology Videos](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOghUHAekUm80Ooh7ohMd8QXE9NpbcQGrxTZHvb7iYx8Eu5fTKjP89HSfC-2F7VGPt66EAYTdDyFqCfpv80TGhln3AEiMcSS-2BUAymhTsy7Q40qQA-3D-3DzUfO_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoRGUNGBcYKZiTmU9Ip9C631iwFpacXJPd6yowmIQbC7TOyWJ8ueZEQ81X8s3wS1uZiVN67FAY4UoWFcHHfm5l-2FV08TpKedgcEKxYFC41B1Q2K0UwaXVU2y45GsSzDi9x4w-3D-3D))
- **Biotech IPO pipeline**, up to ~25 deals possible in 2026; Cardigan (~$350M) pricing expected, follow-through watched post-SpaceX and post-Fed. ([CNBC's "Fast Money"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhIPVwR8Xv9q9VvJzigGgivq1lsuu5hKeSuKWNhCmsNDegQlyTH4TtHpai-2F3PhjXtzdk-2BGBg21E2Sej1ZWmbi1B0Q8-2FmXdBb9WeAxMhjxvnXQ-3D-3DCaq9_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3Vodrnp0uXuIDEsh5mGi2FSQPaI9eX4LCMm8Y5Kfk2wvVlWWaF9kNdwjpcFLdd8b0Ho4PHniUT7M3p2WI2jaVw-2ByhxpwECcWJ8sGinILYlVVqFx2-2FJM7zRc-2BKsH5tQPC5CFA-3D-3D)) ([BioCentury This Week](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgVMFhquD44R1J5rj8fptp-2Fb6UDC4PpVrtCoGaw0Sc6uYa68qj6dDkJqyLIlSXzRczKjNCBxPtmDqH8pxpzIKCS7Mx3zeo4U2ipuzbW0s7WOg-3D-3D13RZ_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoVEHMob9lho3-2FZWI3NyaIoWxRlVbLeJuqFL859xPLcjz7PLE7M7k3PkyjH6p65OuApMMDMiW8xyScOKEAKj0kxNLkaWAbFu2o09skwcFnI2YMY84Dj4P9-2BvuiiYH48dwwg-3D-3D))
- **WuXi AppTec / Biosecure Act litigation**, federal court challenge to the 1260H "Chinese military company" designation; outcome could re-rate CDMO supply-chain risk. ([BioCentury This Week](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgVMFhquD44R1J5rj8fptp-2Fb6UDC4PpVrtCoGaw0Sc6uYa68qj6dDkJqyLIlSXzRczKjNCBxPtmDqH8pxpzIKCS7Mx3zeo4U2ipuzbW0s7WOg-3D-3Dimel_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoXYCpRSPSQ5-2F15QHRDAJdBlE-2FA3tD-2BxvZ44XOdoixHhhZs4QJ-2Bsd26U7NqwzhHsF4i1u56OpfuaD9f7oOHCVWBFGivVxTmZeGal-2FOrUDCqSibVOXl59lSBavKP0CgHYvWg-3D-3D))
- **Lilly tirzepatide autoimmune label expansion**, FDA discussions on together-PSA/PSO "likely to take place in Q2 or Q3 2026." ([Citeline Podcasts](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiQ2xpKMJceGnLpvLMV1q75jNH387i2AoPI2EE1-2BkgW5HEvtOOFBV1R5Gdt8-2Ba87V-2FT9F9nQihXkInZHK69PB4Zny9KItJGWTWYeVtB5ZACIg-3D-3DHBUG_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoZoEs27YJe6ulm71Vn70OSE4eA7B-2FL2BSOb04Lv9z-2B2Zh61MHJD7L77c9fSC-2BlQNyee96SfeIp1MSoY7QS9fJqrtpc2DHSdKwMBpiqaO7qXXFD5WtBCsyVHKK6L89J0rHw-3D-3D))
- **Oncology decisions referenced:** giredestrant (Roche) oral-SERD + everolimus, FDA decision expected December 2026; ongoing Merck "string of pearls" M&A cadence (watch for additional sub-$10B deals). ([OncLive® On Air](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhSO6pDEKyEHu9mv5TPSvfdl9unGR3mS5yLJQ4dlU7PzTfKkBF-2B6KDdkPhnxHvT6LdLErhHMmGbXlUXpgOe-2FIYBVu8p2KkRmZxpiRKoA2nv9g-3D-3DPmhO_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoZqzygdZvxVFltEYNv7Wgfg1tt4ux6OutOhZk0Q0IVORdkp-2Fhy6znHQqjiZhUDMhIc-2F-2B85VqHJ4A-2B7dBzT-2BHiMXRID9QV3IlHDYWddgriCV794o78S1maZD96cnH-2BHbCpA-3D-3D)) ([CNBC's "Fast Money"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhIPVwR8Xv9q9VvJzigGgivq1lsuu5hKeSuKWNhCmsNDegQlyTH4TtHpai-2F3PhjXtzdk-2BGBg21E2Sej1ZWmbi1B0Q8-2FmXdBb9WeAxMhjxvnXQ-3D-3Db5Ci_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3Voe-2FdTRMpGSuz7r7o09z42qiiegxY69JpXEzDooxUfUs9Ljiz90UduDCVkG2o1b6txT00IjzR8LjSxXuX42aiS18jA0OrTo-2Bw1i7IxeiA2fvhv7xHL7aFAzQvXBBD6N6neA-3D-3D))
- **Policy:** AbbVie v. HRSA on the 340B patient definition (D.C. District Court), a ruling could reshape 340B economics for manufacturers. ([340B Unscripted](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjGNn7OAJbp945-2BULJFELiyP-2F5iNllA3mFHBmh-2FthJuqUM1e5cLKnnLcCHqLGDYMZ1JPR4SaNv8I-2FGy7PhkYcfOsxX6yDv7fVVMvdmCug8G7w-3D-3DEzi6_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VoY2pnKuf8j3H8eIPLXRJHZrWLTd9uJPF0ZMem6RIokLH2dNoewe2yDW0xc82LUWlg815KB7fqf1QC9FGa0on7rijksqHe69peAFn-2BAbwA9ZqyYJNhPbVFGmS7O7OQlSMdQ-3D-3D))

## Coverage Gaps

- **Tools / CROs / Diagnostics / Medtech (DHR, TMO, A, IQV, ICLR, CRL, ISRG, MDT, BSX, EW):** no investor-grade coverage this week. Only a molecular-design software CRO episode and a retrospective MedTech-CEO interview surfaced, neither carried stock theses or numbers. Likely a true content gap (no major catalysts for these names in the window).
- **IRA drug-price negotiation mechanics:** thin. No episode covered the 2026 negotiation list or specific drug-class outcomes. The closest was Lumanity's Steve Mather on the strategic convergence of IRA + Most-Favored-Nation pricing + EU Joint Clinical Assessment compressing revenue horizons (IRA: 9-year exclusivity for small molecules, 13 for biologics). ([Outcomes Rocket](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOi24itfKMkA8KVAk2YCqUqrVbv3bOm6rKBdIF7bB19cqOMAzRdq-2FiIRYcTklyw3cw-2BDJd8IU-2FHMxY4gGHvFC2nAV3YwdOvhkjZZJ0q4KlcXlg-3D-3DaOqW_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3Vod8MqJRswrkaWQ1cfS794QzpyEORvpPeEnMVEQ-2F64rcdj-2FiaLhZ-2F-2BxiBXXnwB54AeK2W5X1LE7bFYxOm8k5XxQHJzwvzRr0FohEkVFOYF-2FN4-2FYWiGqntY-2BTaAGjcrOxYIw-3D-3D))
- **China biotech / pharma tariffs:** thin. Beyond the WuXi/Biosecure thread and general reshoring commentary, no dedicated US–China pharma-tariff deep-dive surfaced.
- **RFK Jr. / HHS policy:** light. The Readout Loud ran an "RFK Jr. report card" segment but it was not investment-framed; The Compound's Morgan Stanley episode (Michael Zezas) touched pharma only via a Trump-tweet-at-Pfizer anecdote within a broader multipolar-world macro discussion. ([The Compound and Friends](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg5t6RVV7RK-2Bwmw3sW5XIouktCGiREteIUC88VmP5sfuy7WlieP9DHh53VyvQWsJ-2Bd2VCQDxKelenMZVrOUnp2CfRH5j4nzv6KwcTussc6m0g-3D-3DgotR_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUKnAyHeL6BN2X5DHKmrdVPLXgq98UO-2Bspat4wzTJ3VofVHYoUvdfV7KZpvofUrihuLqRaWKw-2BY1hx-2Biyc9gMxzwR4oTiYbxJ6wx3rDHkDLL09NgTSK-2F-2FRWBBfb4l4d5ss25423cfiSwKTkbRivHn3KuDUvPY-2FC1lr6FjUkCp6qnw-3D-3D))
- **Generalist investor pods** (Invest Like the Best, Acquired, Business Breakdowns, All-In, Odd Lots) and Endpoints News: no qualifying pharma/biotech episodes in the 8-day window.
- **Caveat on oncology depth:** the large ASCO 2026 slate is overwhelmingly clinical/CME content, excellent for thesis-checking drug data, but it names drugs/sponsors without articulating stock bull/bear cases. Treat the Section 3 oncology entries as catalyst/clinical color, not as podcast-sourced investment recommendations.